An early detection of skin cancer is definitively crucial for patient and for the healthcare system. It gives more than 95% chance of recovery, treatment cost at this stage is few thousands Euro, while the 5-years survival rate at advances stages drops as low as 10%, and treatment costs can rise to more than 140.000€.
Overall skin disease is one of the most common human illnesses, more than 1 Billion people are affected by skin conditions and affects between 30% and 70% of individuals. Despite impact, skin disease debate at national and global level is at its early stage. Although apparently skin diseases are perceived as being less severe than other diseases their real impact on quality of life is far more significant.
In most EU countries, access to dermatologist resources are very limited. Dermatologists cannot cope with the general increase demand (population aging, continuous increase of skin cancer incidence, etc) leading to very long waiting list and or missing skin medical care for more critical cases. Efficient triage of patient prior to access a specialist is the future of any efficient healthcare system.
DermoSafe aims to be the 1st patient centric and multi-channels web service platform for dermatology E-triage, skin inflammatory diseases and skin cancer screening by dermoscopy, based on advanced neuronal artificial intelligence network supporting patients, healthcare professionals and our certified board of dermatologists.
The specific objective of the feasibility study was to provide proofs that the concept of DermoBrain, when integrated into our secure E-triage web platform, is technically feasible and commercially scalable with an appropriate business model.
This feasibility study enable us to review our market strategy and refine positioning versus current competition, and especially to gain very important clarification on the compliance and regulation of artificial intelligence within the field of healthcare
